Retevmo The First Therapy Developed for Patients with Advanced RETDriven Lung and Thyroid Cancers

Eli Lilly and Company discovered Retevmo™ (selpercatinib, 40 mg & 80 mg capsules) to treat patients with different types of cancers such as non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancer.

Retevmo™ is the first clinically proven therapy to treat cancer patients with metastatic rearranged during transfection (RET)fusion-positive non-small cell lung cancer (NSCLC). Retevmo™, a kinase inhibitor, blocks a type of enzyme (kinase) and helps preventing the growth of cancer cells. It is applicable for both those who have tried prior systemic medications and those starting treatment for the first time.

Retevmo™  is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who requires systemic therapy. It is also used for the treatment of patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Although Retevmo™ capsules are considered to be the most effective treatment for lung and thyroid cancers often have serious side effects such as increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) enzymes in the liver, increased blood pressure, bleeding and allergic reactions, decreased white blood cell count, decreased albumin in the blood, decreased calcium in the blood, dry mouth, diarrhea, increased creatinine (which can measure kidney function), increased alkaline phosphatase (an enzyme found in the liver and bones), hypertension, fatigue, swelling in the body or limbs, low blood platelet count, increased cholesterol, rash, constipation and decreased sodium in the blood. It also causes harm to a developing fetus or a newborn baby.

Retevmo was approved under the FDA's Accelerated Approval regulations based on the LIBRETTO-001 Phase 1/2 trial's endpoints of Objective Response Rate (ORR) and Duration of Response (DoR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.